DRCR Protocol T was a randomized trial that compared aflibercept, bevacizumab, and ranibizumab in center-involving diabetic macular edema.

It remains the main head-to-head comparison for these three drugs in this disease, and its subgroup results by baseline acuity guide the choice of the first agent.


Design of DRCR Protocol T

The trial enrolled 660 eyes with vision loss from center-involving diabetic macular edema, and eyes received aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab 0.3 mg, with protocol-driven retreatment and laser rescue.

The primary outcome was the mean change in visual acuity at one year, with follow-up to two years. Wells and colleagues published the one-year results in the New England Journal of Medicine.

One-Year Results of DRCR Protocol T

Visual acuity improved in all groups, and the difference by drug depended on the baseline acuity. Among eyes with baseline acuity of 20/40 or better, the three drugs gave similar gains.

Among eyes with baseline acuity of 20/50 or worse, aflibercept gave greater improvement than bevacizumab and ranibizumab at one year. So the authors concluded that the choice depends on the starting vision (see diabetic macular edema).

Test your knowledge 10 questions from this article
Choroida · Fundus imaging

Fundus Explorer Pro

Photograph the retinal findings described here with the phone already in your pocket — 22 D optics and built-in illumination in one handheld unit.

From Choroida — the team behind this site

Two-Year Results

Aflibercept stayed superior to bevacizumab in eyes with worse baseline acuity. However, the difference between aflibercept and ranibizumab narrowed and was no longer significant at two years. Wells and colleagues also reported a numerically higher rate of cardiovascular events with ranibizumab in the second year, though the trial was not powered for safety.

How to Apply DRCR Protocol T

  • With good baseline vision, start with the least costly agent, often bevacizumab
  • With worse baseline vision, consider aflibercept first
  • Switch agents when the response is inadequate after several injections
  • Add laser or steroids in selected eyes

Cost and access often decide the real choice (see anti-VEGF therapy).

Limits of DRCR Protocol T

The trial tested older formulations and regimens, and newer agents entered later. It did not measure long-term anatomic outcomes beyond two years, and real-world patients have more comorbidity and irregular follow-up, so apply the results with flexibility.

Practical Points

Record baseline acuity and thickness before treatment, then switch after an inadequate response and document the reason, and discuss cost, convenience, and safety with the patient.

An Example Case

A 58-year-old man with center-involving diabetic macular edema has acuity of 20/80 and central thickness of 480 micrometers. His clinician reviews the Protocol T results and chooses aflibercept as the first agent because of his worse baseline vision.

After six monthly injections, his acuity reaches 20/40, and the thickness falls to 310 micrometers, and he then continues on an extended schedule.

DRCR Protocol T: Aflibercept, Bevacizumab or Ranibizumab

Questions Patients Ask

Patients ask which injection is best, and the answer depends on baseline vision, cost, and availability. They also ask whether the cheaper drug works as well, and for good baseline vision the results were similar. Because the decision involves cost, explain that bevacizumab is a reasonable first choice in many cases.

Pitfalls to Avoid

  • Applying the results to eyes with very poor vision or ischemia without caution
  • Ignoring the need to switch agents when the response is inadequate
  • Forgetting laser or steroids in eyes that respond poorly
  • Assuming that the same drug is best for every patient

Looking Ahead

Newer agents, such as faricimab and high-dose aflibercept, have since entered practice with long-interval regimens, and comparative trials of these agents against older drugs continue. Therefore, treat Protocol T as a starting point, not the final word.

Practical Points

Document baseline acuity, thickness, and prior treatment, then set a time to assess response, such as after three monthly injections, and also discuss insurance requirements for step therapy.

Safety Observations in DRCR Protocol T

The trial found similar rates of serious adverse events across groups, with a few differences in the second year. Because patients with diabetes have high cardiovascular risk, monitor blood pressure and lipids and also review systemic history before each treatment.

Cost and Access

Bevacizumab costs far less than aflibercept or ranibizumab, and in many health systems, payers require a trial of the cheaper drug first. Therefore, Protocol T gives clinical support to step therapy in eyes with good vision.

Reading the Subgroup Table

The authors prespecified subgroups by baseline acuity, so the results by subgroup are reliable. They also report the change in letters and the proportion that gained at least 15 letters, so review the table when you counsel patients about expectations.


All-fit smartphone adapter on a slit lampFundus Explorer Pro smartphone fundus camera
Choroida · Clinical imaging

Document what you see

Two smartphone imaging tools built for everyday clinic use — one for the slit lamp, one for the fundus.

From Choroida — the team behind this site

References

  1. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-1203.
  2. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351-1359.
  3. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern. Ophthalmology. 2020;127:P66-P145.
  4. American Academy of Ophthalmology. Basic and Clinical Science Course, Section 12: Retina and Vitreous. AAO; current edition.

Test yourself

A few questions straight from this article.

1 / 10 0 correct
  1. DRCR Protocol T compared aflibercept, bevacizumab and ranibizumab head to head in which condition?

Ahmed Ophthalmologist

Writes and reviews the clinical articles on Educate. Every post is checked against peer-reviewed sources before it goes live.